Homoeopathic treatment of respiratory sequelae of post- covid cases: an open label prospective study
- Registration Number
- CTRI/2021/03/032225
- Lead Sponsor
- Dr Anil Khurana
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Age 18-80 years
2.Previously positive COVID cases (ICD code: U07.1)
3.Patient who tested to be COVID-19 negative, 4 weeks after discharge from COVID Care Centre.
4.Patient presenting with any of the respiratory symptoms such as - shortness of breath, cough, expectoration, chest pain and other respiratory complaints (ICD code: B97.29)
5.HRCT confirmed cases of COVID Lung Damage like ground glass opacities and fibrosis
6.PFT with features of restriction evidenced by FVC < 80% and FeV1 < 80% of the predicted value ( ATS-ERS recommendation/ guideline)
7.Willing to give consent in writing
1.Patients who are tested to be COVID-19 positive, at the time of enrollment in the study.
2.Patient with previous history of COPD, Asthma, Bronchiectesis and Chronic Cardiac ailments
3.Pregnant and lactating women
4.Patients who are not willing to volunteer for the study.
5.Patients developing serious complications, Immuno-compromisedpatients
6.Idiosyncratic reactions, severe medicinal aggravation and requiring ventilator support or emergency surgical intervention.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the role of homoeopathic treatment in Respiratory sequelae of Post COVID cases.Timepoint: at 3 months
- Secondary Outcome Measures
Name Time Method To study the time of recoveryTimepoint: at 3 months